RNAi Biotech Atalanta Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases
Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing levels of certain proteins in the central nervous system …